In this guide
What is PQQ?
Pyrroloquinoline quinone, abbreviated PQQ, is a small redox-active quinone. It functions as an enzyme cofactor in some bacteria and appears in trace amounts in foods, but it is not recognized as an essential human vitamin. Retail supplements generally use PQQ disodium salt, sometimes inside a “mitochondrial support” formula with CoQ10 or other ingredients.
Laboratory work links PQQ to redox reactions and signalling involved in mitochondrial biogenesis. That mechanism is a research rationale, not a clinical result. Human studies remain small and short: selected cognitive tests and physical-function measures changed in some product-linked trials, while a supervised exercise trial found no aerobic-performance or body-composition advantage. No human trial shows longer life. [1]–[4]

Typical PQQ Protocols
| Study and population | Product | Amount each administration | Daily total | Frequency and duration | Main interpretation |
|---|---|---|---|---|---|
| Shiojima 2022 · 64 healthy Japanese adults aged 40 to under 80 | mnemoPQQ disodium salt | Not reported in abstract | 21.5 mg/day | Administration count not reported; 12 weeks | 58 completed; selected cognitive-domain scores favored PQQ in a product-linked study |
| Tamakoshi 2023 · healthy younger and older adults | PQQ disodium salt | Not reported in abstract | 20 mg/day | Administration count not reported; 12 weeks | Age-stratified selected memory and cognitive-flexibility signals; multiple outcomes and industry affiliations |
| Hwang 2020 · 23 untrained men during supervised endurance training | PQQ | Not reported in abstract | 20 mg/day | Administration count not reported; 6 weeks | PGC-1α protein changed, but aerobic performance and body composition did not improve versus placebo |
| Shiojima 2024 · 64 healthy Japanese adults aged 20 to under 75 | Novel PQQ disodium salt | Not reported in abstract | 21.5 mg/day | Administration count not reported; 12 weeks | Selected lower-limb strength and walking measures changed in a product-linked study |
These rows are records of four specific studies, not a dosing recommendation. Even where a paper reports “mg/day,” that does not establish whether participants swallowed one or several units unless the methods say so. Recording a guessed once-daily schedule would make the evidence look more precise than it is.
The trials also answer different questions. A cognitive score, PGC-1α protein level, walking measure and aerobic-performance test cannot be pooled into one “mitochondrial health” response. [1]–[4]
- Chemical form
- Record PQQ disodium salt and the named ingredient when available; do not assume every PQQ raw material matches BioPQQ or mnemoPQQ.
- Administration count
- Separate the reported 20–21.5 mg daily total from the per-administration amount, which several abstracts do not report.
- Outcome
- Choose cognition, exercise performance, strength or tolerability before reviewing the record; a pathway marker is a different endpoint.
What is PQQ commonly used for?
Cognition and memory
The 2022 Shiojima trial randomized 64 healthy Japanese adults and reported 58 completers after 12 weeks. Several composite or domain scores favored 21.5 mg/day PQQ disodium salt. A later 20 mg/day study reported different age-stratified signals. These are leads, but small samples, multiple cognitive outcomes, healthy volunteer populations and product-linked researchers make independent replication important. [1], [2]
Exercise and physical function
In 23 untrained men completing supervised endurance training, 20 mg/day for six weeks changed skeletal-muscle PGC-1α protein. It did not improve aerobic performance or body composition versus placebo. A separate 64-person, 12-week study reported selected lower-limb strength and walking changes at 21.5 mg/day, but it was also product linked. Neither study establishes a general performance enhancer. [3], [4]
Energy, fatigue and mitochondrial support
PQQ marketing often moves directly from redox chemistry to “cellular energy.” Human trials do not support that broad translation. A person may perceive an energy change, but the research must still specify a validated symptom scale or functional test. PGC-1α is a signalling marker; it is not energy, VO2max, recovery or daily function.
Healthy aging and longevity
No human PQQ trial demonstrates longer lifespan, slower biological aging or reduced age-related disease. Short cognitive and walking outcomes cannot stand in for those endpoints. Calling a compound “mitochondrial” does not supply the missing clinical evidence.
Translation check
A pathway marker is not the finish line
Each arrow requires evidence. The marker cannot substitute for the functional result.
How do forms and labels differ?
Most researched products use PQQ disodium salt. A label may list the total salt mass, a branded ingredient or PQQ content; those descriptions should not be assumed equivalent without a specification. BioPQQ is the defined ingredient in EFSA’s safety opinion. mnemoPQQ is the product name in the 2022 cognitive trial. Evidence for either belongs to that material and formulation.
Combination products add another problem. A PQQ plus CoQ10, alpha-lipoic acid or carnitine formula cannot borrow a single-ingredient PQQ result, and any change cannot be assigned to PQQ alone. Record every active ingredient and its amount.
How should PQQ be stored?
Keep the finished product sealed, dry and protected from heat and direct light. Follow its label for temperature, desiccant, expiry and refrigeration. Discard capsules with damaged seals, moisture or unexplained colour or odour changes. Product switches should be recorded because raw material, strength and co-ingredients may change together.
What does the human evidence show?

| Question | Evidence | Finding | Boundary |
|---|---|---|---|
| Does PQQ improve cognition in healthy adults? | Small 12-week product-linked RCTs | Selected scores favored PQQ | Multiple outcomes; independent replication needed |
| Does it improve endurance performance? | 23-person, 6-week training RCT | No aerobic-performance advantage | Small male sample |
| Does it alter a mitochondrial-biogenesis marker? | Same exercise RCT | PGC-1α protein changed | Marker did not translate into performance |
| Does it improve physical function? | 64-person, 12-week product-linked RCT | Selected strength and walking measures changed | Healthy volunteers; short study |
| Does it extend life or healthspan? | No human outcome trial | Not established | Mechanism cannot replace a longevity endpoint |
Human evidence map
Small trials produce leads, not a universal promise
Replication by independent groups and clinically meaningful outcomes remain important gaps.
The most informative negative result is the exercise trial’s mismatch between marker and outcome. PGC-1α protein changed, yet aerobic performance did not. That result directly limits claims that a molecular signal proves better energy production or endurance. [3]
The positive studies also need outcome discipline. A selected cognitive-domain or walking result may justify another trial; it does not establish dementia prevention, treatment of cognitive impairment, fall prevention or healthy-aging benefit. [1], [2], [4]
What are the risks and interactions?
Short human studies reported few adverse events, but that is not the same as comprehensive long-term safety. Digestive upset, headache, sleep change, rash or other new symptoms should be recorded. Stop and seek urgent care for severe allergy, fainting, persistent vomiting or a marked neurological change.
EFSA concluded that the assessed BioPQQ disodium salt was safe at the intended maximum of 20 mg/day for healthy adults, excluding pregnant and lactating people. That conclusion applies to a defined ingredient and intended population. It is not a universal tolerable upper limit, a proven effective dose or permission to extrapolate high-dose animal kidney findings into a human threshold. Human renal-safety data were limited. [5]
People with kidney or liver disease, pregnancy, breastfeeding, planned surgery, unexplained cognitive symptoms or complex medication regimens should obtain clinician review. Direct interaction data are sparse; absence of a documented interaction is not proof of compatibility. Multi-ingredient products inherit every co-ingredient’s risks.
What is the legal and regulatory status?
In the United States, products marketed as PQQ supplements fall under the dietary-supplement framework. Manufacturers are responsible for safety and compliant labelling before marketing, while FDA can act against adulterated or misbranded products after market entry. PQQ is not FDA-approved to treat cognitive decline, fatigue, mitochondrial disease or aging. [6]
In Canada, PQQ products sold as natural health products require product authorization and an NPN or DIN-HM. Canadian authorization, US supplement marketing and the European novel-food safety opinion are different regulatory decisions. None establishes the clinical effectiveness of every PQQ product.
What happens when you stop?
PQQ has no established withdrawal syndrome and no evidence-based taper. If a perceived effect depends on continued exposure, it may move toward baseline after stopping. A planned stop date can help distinguish a stable pattern from daily variation, but worsening cognition, weakness or unexplained fatigue needs medical assessment rather than repeated supplement cycling.
What should you monitor?
Record the chemical form, branded raw material, strength, amount at each administration, daily total, timing, start date and co-ingredients. Choose one or two outcomes in advance: a consistent cognitive task, a validated fatigue scale, an exercise test or a clinician-defined physical-function measure.
Review after a fixed window rather than reacting to a single day. Track sleep, GI symptoms, headache, rash and changes in medication or training. Stop and seek review for persistent or severe symptoms. Kidney or liver laboratory testing should be clinician-directed; a supplement log cannot interpret an abnormal result.
What does community experience add?
Public reports may surface sleep changes, headache, GI intolerance, capsule size, cost and confusion about combination products. They cannot verify mitochondrial biogenesis, prevent dementia or establish a responder rate. No systematic current community sample was assembled for this guide, so it reports no consensus dose, brand or expected effect.
How does PQQ compare with related options?
| Option | Practical distinction | Evidence boundary |
|---|---|---|
| PQQ disodium salt | Form used in the cited cognition and function studies | Small, short, mostly product-linked evidence |
| CoQ10 | Endogenous electron carrier with indication-specific clinical trials | Cannot inherit PQQ outcomes |
| Alpha-lipoic acid | Distinct cofactor with neuropathy and metabolic research | Different doses, risks and clinical questions |
| Creatine | Better-established exercise supplement for repeated high-intensity work | Different mechanism and performance evidence |
| Sleep, exercise and medical evaluation | Address common causes of fatigue or cognitive complaints | Supplement testing should not delay diagnosis |
Common questions
Is PQQ a vitamin?
No. It acts as a cofactor in some bacteria, but humans have no established PQQ deficiency syndrome, RDA or essential-vitamin status.
Does PQQ improve memory?
Small 12-week trials reported selected cognitive-score signals at 20–21.5 mg/day. The evidence needs larger independent replication and does not establish prevention or treatment of cognitive disease. [1], [2]
Does it increase mitochondria?
Preclinical studies support a mitochondrial-biogenesis rationale. One small human exercise study changed PGC-1α protein, but aerobic performance did not improve. That is not proof of a clinically useful increase in mitochondria. [3]
Is 20 mg a proven effective dose?
No. It is a common daily total in small human trials and the maximum intended use EFSA evaluated for one ingredient. A studied or assessed amount is not universally effective. [1]–[5]
Is PQQ a longevity supplement?
It is marketed that way, but no human trial shows longer lifespan, slower aging or broad healthspan improvement.
Can PQQ be combined with CoQ10?
Combination products exist, but each compound has separate evidence. A blend also makes causality harder to interpret and adds every ingredient’s interaction profile.
Should kidney function be monitored?
Human renal-safety data are limited, while EFSA’s conclusion was ingredient- and population-specific. People with kidney disease or abnormal tests should involve a clinician rather than choosing a monitoring plan from animal data. [5]
Glossary
Plain explanations of PQQ research terms.
- PQQ
- Pyrroloquinoline quinone, a redox-active quinone sold as a supplement, often in disodium-salt form.
- Redox
- Chemical transfer of electrons between oxidized and reduced states.
- PGC-1α
- A regulatory protein involved in cellular energy and mitochondrial-biogenesis signalling; a marker, not a clinical outcome.
- Mitochondrial biogenesis
- Cellular processes that regulate mitochondrial content and components.
- Product-linked study
- A study with manufacturer funding, employee authors or other commercial involvement that should remain visible beside its result.
- Novel food opinion
- A safety assessment for a defined ingredient and intended conditions of use; it does not prove efficacy.
How this guide was researched
Each PubMed identifier and DOI was checked against the displayed title, authors and source type. Daily totals were extracted separately from amount per administration and administration count. Product links, small samples, multiple outcomes and the null exercise-performance result remain visible.
Research record · checked October 9, 2026
Fresh reads: four human PQQ trials, the EFSA safety opinion and current FDA supplement oversight.
Identity verification: PMID 34415830 is Shiojima et al.; PMID 36807425 is Tamakoshi et al.; PMID 31860387 is Hwang et al.; DOI 10.1016/j.jff.2024.106012 is the 2024 Shiojima physical-function trial.
Protocol extraction: studies reported 20 or 21.5 mg/day for 6 or 12 weeks; per-administration amount was left unreported where the abstract did not supply it.
Correction review: PMID 35917215 reports minor errors in Table 4 that were corrected in the article; the notice does not specify the edited cells. This guide avoids Table 4 values and uses only protocol, participant flow and selected cognitive-domain findings independently present in the PubMed abstract.
Commercial context: product-linked investigators and industry affiliations are retained beside positive findings.
Negative evidence: the changed PGC-1α marker remains beside null aerobic-performance and body-composition outcomes.
Explore the sources
Primary human trials and current official safety and regulatory guidance.
Showing 6 sources
- 01
Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. ↗
Randomized controlled trial
21.5 mg/day for 12 weeks, participant flow, selected cognitive scores and product links.
- 02
Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults. ↗
Randomized controlled trial
20 mg/day, age-stratified findings, multiple outcomes and affiliations.
- 03
Effects of Pyrroloquinoline Quinone (PQQ) Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men. ↗
Randomized training trial
20 mg/day for six weeks, changed PGC-1α protein and null aerobic-performance and body-composition findings.
- 04
Efficacy and safety of a novel dietary pyrroloquinoline quinone disodium salt on muscle strength and physical function in healthy volunteers ↗
Randomized controlled trial
21.5 mg/day for 12 weeks, selected physical-function results and product links.
- 05
Safety of pyrroloquinoline quinone disodium salt as a novel food pursuant to Regulation (EC) No 258/97 ↗
Official scientific opinion
Ingredient-specific 20 mg/day intended-use conclusion, excluded populations and limited human safety evidence.
- 06
Dietary Supplements ↗
Official regulatory overview
Manufacturer responsibility, supplement oversight and post-market enforcement framework.
No matching sources
Try a different term or show the full list.
Editorial note
This guide keeps PQQ’s redox and mitochondrial rationale separate from markers, functional tests and unmeasured longevity outcomes.